Aurobindo Pharma’s Telangana facility gets VAI classification from USFDA

The US Food Drug and Administration (USFDA) has concluded that the inspection classification of Aurobindo Pharma’s API intermiediate facility of Telangana is Voluntary Action Indicated (VAI).
As per the information available on the United States Food and Drug Administration website, the company’s Unit – IX, an API intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana, which was inspected by the United States Food and Drug Administration from November 10 to November 18, 2022, has now been classified as Voluntary Action Indicated (VAI).
In November 2022, USFDA had issued 10 observations after the inspection of the pharma company’s Unit-IX. The unit was classified as Official Action Indicated (OAI) on 17 May 2019, and the company had carried out the required corrective actions.
Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.
Source: Business-standard

Gubba Group

About the author

Gubba Group: